platON™ is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds that broaden the Company’s product pipeline.
AsiDNA™, the first compound sourced from platON™, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy mechanism with an agonist effect, acting upstream of multiple DDR pathways. AsiDNA™ has the ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA™ has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy, radiotherapy and PARP inhibitors. Thanks to a good safety profile, AsiDNA™ is particularly amenable to combination treatment, a standard of care in aggressive or resistant cancers. AsiDNA™ is currently evaluated in the DRIIV-1b phase 1b study in combination with chemotherapy and the REVOCAN phase 1b/2 study in combination with PARP inhibitor niraparib in relapsed ovarian cancer.
OX401 is the second drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. In vivo, OX401 has shown a potent antitumoral activity and a strong immune response activation. Preclinical proof of its activity in combination with check point inhibitors is being investigated.